Overexpression of the potential kinase serine/threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer

Suyoun Chung, Kenji Tamura, Mutsuo Furihata, Motohide Uemura, Yataro Daigo, Yasutomo Nasu, Tsuneharu Miki, Taro Shuin, Tomoaki Fujioka, Yusuke Nakamura, Hidewaki Nakagawa

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Despite high response rates and clinical benefits, androgen ablation often fails to cure advanced or relapsed prostate cancer because castration-resistant prostate cancer (CRPC) cells inevitably emerge. CRPC cells not only grow under castration, but also behave more aggressively, indicating that a number of malignant signaling pathways are activated in CRPC cells as well as androgen receptor signaling. Based on information from the gene expression profiles of clinical CRPC cells, we here identified one overexpressed gene, serine/threonine/tyrosine kinase 1 (STYK1), encoding a potential kinase, as a molecular target for CRPC. RNA and immunohistochemical analyses validated the overexpression of STYK1 in prostate cancer cells, and its expression was distinct in CRPC cells. Knockdown of STYK1 by siRNA resulted in drastic suppression of prostate cancer cell growth and, concordantly, enforced expression of STYK1 promoted cell proliferation, whereas ectopic expression of a kinase-dead mutant STYK1 did not. An in vitro kinase assay using recombinant STYK1 demonstrated that STYK1 could have some potential as a kinase, although its specific substrates are unknown. These findings suggest that STYK1 could be a possible molecular target for CRPC, and small molecules specifically inhibiting STYK1 kinase could be a possible approach for the development of novel CRPC therapies. (Cancer Sci 2009).

Original languageEnglish
Pages (from-to)2109-2114
Number of pages6
JournalCancer Science
Volume100
Issue number11
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Protein-Serine-Threonine Kinases
Castration
Protein-Tyrosine Kinases
Prostatic Neoplasms
Phosphotransferases
Androgen Receptors
Transcriptome
Small Interfering RNA
Androgens
Cell Proliferation
RNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Overexpression of the potential kinase serine/threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. / Chung, Suyoun; Tamura, Kenji; Furihata, Mutsuo; Uemura, Motohide; Daigo, Yataro; Nasu, Yasutomo; Miki, Tsuneharu; Shuin, Taro; Fujioka, Tomoaki; Nakamura, Yusuke; Nakagawa, Hidewaki.

In: Cancer Science, Vol. 100, No. 11, 11.2009, p. 2109-2114.

Research output: Contribution to journalArticle

Chung, S, Tamura, K, Furihata, M, Uemura, M, Daigo, Y, Nasu, Y, Miki, T, Shuin, T, Fujioka, T, Nakamura, Y & Nakagawa, H 2009, 'Overexpression of the potential kinase serine/threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer', Cancer Science, vol. 100, no. 11, pp. 2109-2114. https://doi.org/10.1111/j.1349-7006.2009.01277.x
Chung, Suyoun ; Tamura, Kenji ; Furihata, Mutsuo ; Uemura, Motohide ; Daigo, Yataro ; Nasu, Yasutomo ; Miki, Tsuneharu ; Shuin, Taro ; Fujioka, Tomoaki ; Nakamura, Yusuke ; Nakagawa, Hidewaki. / Overexpression of the potential kinase serine/threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. In: Cancer Science. 2009 ; Vol. 100, No. 11. pp. 2109-2114.
@article{db6b1408760e4aa7971b490342887030,
title = "Overexpression of the potential kinase serine/threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer",
abstract = "Despite high response rates and clinical benefits, androgen ablation often fails to cure advanced or relapsed prostate cancer because castration-resistant prostate cancer (CRPC) cells inevitably emerge. CRPC cells not only grow under castration, but also behave more aggressively, indicating that a number of malignant signaling pathways are activated in CRPC cells as well as androgen receptor signaling. Based on information from the gene expression profiles of clinical CRPC cells, we here identified one overexpressed gene, serine/threonine/tyrosine kinase 1 (STYK1), encoding a potential kinase, as a molecular target for CRPC. RNA and immunohistochemical analyses validated the overexpression of STYK1 in prostate cancer cells, and its expression was distinct in CRPC cells. Knockdown of STYK1 by siRNA resulted in drastic suppression of prostate cancer cell growth and, concordantly, enforced expression of STYK1 promoted cell proliferation, whereas ectopic expression of a kinase-dead mutant STYK1 did not. An in vitro kinase assay using recombinant STYK1 demonstrated that STYK1 could have some potential as a kinase, although its specific substrates are unknown. These findings suggest that STYK1 could be a possible molecular target for CRPC, and small molecules specifically inhibiting STYK1 kinase could be a possible approach for the development of novel CRPC therapies. (Cancer Sci 2009).",
author = "Suyoun Chung and Kenji Tamura and Mutsuo Furihata and Motohide Uemura and Yataro Daigo and Yasutomo Nasu and Tsuneharu Miki and Taro Shuin and Tomoaki Fujioka and Yusuke Nakamura and Hidewaki Nakagawa",
year = "2009",
month = "11",
doi = "10.1111/j.1349-7006.2009.01277.x",
language = "English",
volume = "100",
pages = "2109--2114",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Overexpression of the potential kinase serine/threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer

AU - Chung, Suyoun

AU - Tamura, Kenji

AU - Furihata, Mutsuo

AU - Uemura, Motohide

AU - Daigo, Yataro

AU - Nasu, Yasutomo

AU - Miki, Tsuneharu

AU - Shuin, Taro

AU - Fujioka, Tomoaki

AU - Nakamura, Yusuke

AU - Nakagawa, Hidewaki

PY - 2009/11

Y1 - 2009/11

N2 - Despite high response rates and clinical benefits, androgen ablation often fails to cure advanced or relapsed prostate cancer because castration-resistant prostate cancer (CRPC) cells inevitably emerge. CRPC cells not only grow under castration, but also behave more aggressively, indicating that a number of malignant signaling pathways are activated in CRPC cells as well as androgen receptor signaling. Based on information from the gene expression profiles of clinical CRPC cells, we here identified one overexpressed gene, serine/threonine/tyrosine kinase 1 (STYK1), encoding a potential kinase, as a molecular target for CRPC. RNA and immunohistochemical analyses validated the overexpression of STYK1 in prostate cancer cells, and its expression was distinct in CRPC cells. Knockdown of STYK1 by siRNA resulted in drastic suppression of prostate cancer cell growth and, concordantly, enforced expression of STYK1 promoted cell proliferation, whereas ectopic expression of a kinase-dead mutant STYK1 did not. An in vitro kinase assay using recombinant STYK1 demonstrated that STYK1 could have some potential as a kinase, although its specific substrates are unknown. These findings suggest that STYK1 could be a possible molecular target for CRPC, and small molecules specifically inhibiting STYK1 kinase could be a possible approach for the development of novel CRPC therapies. (Cancer Sci 2009).

AB - Despite high response rates and clinical benefits, androgen ablation often fails to cure advanced or relapsed prostate cancer because castration-resistant prostate cancer (CRPC) cells inevitably emerge. CRPC cells not only grow under castration, but also behave more aggressively, indicating that a number of malignant signaling pathways are activated in CRPC cells as well as androgen receptor signaling. Based on information from the gene expression profiles of clinical CRPC cells, we here identified one overexpressed gene, serine/threonine/tyrosine kinase 1 (STYK1), encoding a potential kinase, as a molecular target for CRPC. RNA and immunohistochemical analyses validated the overexpression of STYK1 in prostate cancer cells, and its expression was distinct in CRPC cells. Knockdown of STYK1 by siRNA resulted in drastic suppression of prostate cancer cell growth and, concordantly, enforced expression of STYK1 promoted cell proliferation, whereas ectopic expression of a kinase-dead mutant STYK1 did not. An in vitro kinase assay using recombinant STYK1 demonstrated that STYK1 could have some potential as a kinase, although its specific substrates are unknown. These findings suggest that STYK1 could be a possible molecular target for CRPC, and small molecules specifically inhibiting STYK1 kinase could be a possible approach for the development of novel CRPC therapies. (Cancer Sci 2009).

UR - http://www.scopus.com/inward/record.url?scp=71049181019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71049181019&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2009.01277.x

DO - 10.1111/j.1349-7006.2009.01277.x

M3 - Article

C2 - 19664042

AN - SCOPUS:71049181019

VL - 100

SP - 2109

EP - 2114

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -